Luke Walker
Director Técnico/Científico/I+D en HARPOON THERAPEUTICS, INC. .
Fortuna: 796 204 $ al 30/04/2024
Cargos activos de Luke Walker
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
HARPOON THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 03/10/2022 | - |
ZENTALIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 29/05/2024 | - |
Independent Dir/Board Member | 29/05/2024 | - |
Historial de carrera de Luke Walker
Antiguos cargos conocidos de Luke Walker.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Director Técnico/Científico/I+D | - | 09/03/2018 |
SEAGEN INC. | Corporate Officer/Principal | - | - |
Formación de Luke Walker.
University of Oklahoma | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Luke Walker
- Experiencia